This study is researching a treatment for a type of blood cancer called Multiple Myeloma. The treatment involves a special drug called Belantamab Mafodotin, which is a combination of an antibody and a drug. An antibody is a protein that helps the immune system fight off harmful substances, and this one targets a specific part of the cancer cells called B-cell maturation antigen (BCMA). The study is in Phase I/II, which means it’s testing the safety and effectiveness of the drug by giving it to people who have had the cancer return after treatment (called relapsed) or if the cancer didn't respond to treatments (called refractory).

• The study involves multiple treatments that will be tested together.
• Participants must be 18 years or older with a confirmed diagnosis of Multiple Myeloma.
• Potential risks include side effects from the treatment and other health complications.